NIH Reporter #5R01AR078892-05

NIAMS Award to Emory University for Small Molecule Inhibitor Development in Spinal Fusion

This opportunity involves the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the National Institutes of Health, awarding Emory University funding for a research project focused on spinal fusion enhancement. - Government Buyer: - National Institutes of Health (NIH) - National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) - Project performed at Emory University, Atlanta, GA - OEMs and Vendors: - No specific OEMs or commercial vendors are named in the notice - Products/Services Requested: - Research and development services for small molecule drug discovery - Development of a novel small molecule inhibitor to locally inhibit noggin (a natural BMP antagonist) - Goal: Promote spinal fusion using lower doses of bone morphogenetic protein (BMP) - No specific product part numbers or commercial products are listed - Unique/Notable Requirements: - Focus on local inhibition of noggin to enhance spinal fusion - Emphasis on reducing required BMP dosage for improved safety and efficacy - Classified under NAICS code 237110 (Water and Sewer Line and Related Structures Construction, likely used for administrative purposes) - No unique license requirements or proprietary technology specified - Estimated and awarded contract value: $339,326 - Period of performance: Multi-year project spanning approximately five years

Description

This project aims to develop a novel small molecule inhibitor to locally inhibit noggin, a natural BMP antagonist, to promote spinal fusion with lower BMP doses, thereby improving safety and efficacy. The procurement is funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under solicitation number 5R01AR078892-05. The project is conducted by Emory University in Atlanta, GA, and spans from July 20, 2022, to June 30, 2027. The estimated contract value is $339,326 with a response deadline of July 30, 2026, and a pre-bid meeting scheduled for July 15, 2026, via Zoom.

View original listing